In short
Clinical trials are currently underway to assess the safety, tolerability, and immunogenicity of V116, a new 21-valent pneumococcal conjugate vaccine. These studies aim to evaluate the vaccine's potential in preventing pneumococcal disease in various populations, including adults at increased risk, older adults, and children and adolescents with higher risk factors. The trials compare V116 to existing pneumococcal vaccines and measure immune responses and adverse events to determine its effectiveness and safety profile.
At a glance
- Vaccine Name
- V116 (Pneumococcal 21-valent Conjugate Vaccine)
- Study Phases
- Phase 3
- Study Populations
- Adults 18-64 at increased risk, Adults 50+, Children and adolescents at higher risk
- Primary Objectives
- Safety, tolerability, immunogenicity
- Comparator Vaccines
- PPSV23, PCV15
- Key Immune Measurements
- OPA GMTs, IgG GMCs, ≥4-fold rise in antibody levels
- Safety Assessments
- Injection-site AEs, systemic AEs, vaccine-related SAEs
- Administration Route
- Intramuscular injection
- Dose
- 0.5 mL
What is Pneumococcal Disease?
Pneumococcal disease is a serious infection caused by bacteria called Streptococcus pneumoniae, also known as pneumococcus. This disease can lead to various health problems, including pneumonia (lung infection), meningitis (infection of the covering of the brain and spinal cord), and bloodstream infections. It's particularly dangerous for young children, older adults, and people with certain medical conditions.
Understanding the Vaccine Component
The PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N CONJUGATED TO CRM197 is a specific component of a new vaccine called V116. This vaccine is designed to protect against pneumococcal disease. The "9N" refers to a specific type (serotype) of pneumococcus that the vaccine targets. "CRM197" is a carrier protein that helps boost the immune response to the vaccine.
Clinical Trials and Research
Several clinical trials are currently underway to evaluate the safety and effectiveness of V116, which includes the PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N CONJUGATED TO CRM197 component. These studies are being conducted in different age groups and populations:
- Adults aged 18 to 64 years with increased risk for pneumococcal disease
- Adults 50 years of age or older
- Children and adolescents with increased risk of pneumococcal disease
These trials aim to assess how well the vaccine stimulates the immune system and its safety profile in different groups of people.
Who Can Benefit from This Vaccine?
Based on the ongoing clinical trials, the V116 vaccine, which includes the PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N CONJUGATED TO CRM197 component, may potentially benefit:
- Adults with increased risk for pneumococcal disease due to conditions such as:
- Diabetes mellitus
- Chronic liver disease
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Chronic heart disease
- Chronic kidney disease
- Adults aged 50 years or older
- Children and adolescents with increased risk of pneumococcal disease due to similar conditions as adults
Safety and Effectiveness
The clinical trials are designed to evaluate both the safety and effectiveness of the V116 vaccine. Researchers are looking at:
- The proportion of participants who experience adverse events (side effects)
- The immune response to the vaccine, measured by:
- Opsonophagocytic activity (OPA): This measures how well antibodies produced by the vaccine can help immune cells engulf and destroy pneumococcal bacteria
- Immunoglobulin G (IgG) levels: These are antibodies produced by the immune system in response to the vaccine
Administration and Dosage
The V116 vaccine, which includes the PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N CONJUGATED TO CRM197 component, is administered as an intramuscular injection. The typical dose is 0.5 ml.
Potential Side Effects
As with any vaccine, there may be potential side effects. The clinical trials are carefully monitoring for both local reactions at the injection site and systemic reactions. Common side effects of vaccines may include:
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle pain
- Fever
It's important to note that the occurrence and severity of side effects can vary from person to person. The ongoing clinical trials will provide more detailed information about the safety profile of this vaccine.